Joseph Schwartz
Stock Analyst at Leerink Partners
(3.22)
# 1,031
Out of 4,937 analysts
139
Total ratings
33.85%
Success rate
18.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $18 → $20 | $12.40 | +61.36% | 6 | Jul 7, 2025 | |
| INSM Insmed | Maintains: Outperform | $100 → $115 | $109.55 | +4.97% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $6.49 | +85.04% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $13.00 | +115.38% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $16.94 | +136.13% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.43 | +3,189.47% | 2 | Sep 19, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.08 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $6.29 | +90.78% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $1.53 | +422.88% | 2 | Jun 20, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.40 | -28.57% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $4.27 | +40.52% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $45.38 | +5.77% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $20.15 | -10.67% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $41.64 | -18.35% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $57.33 | +126.76% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $18.23 | +777.67% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $191.49 | -14.88% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.76 | +468.18% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.07 | +2,984.11% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $11.37 | +5.54% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $27.54 | +292.16% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $26.85 | +45.25% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $0.81 | +395.66% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $12.68 | +136.59% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $46.29 | +8.01% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $51.06 | -41.25% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $13.28 | +321.69% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.77 | +106.95% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.17 | +453.00% | 2 | Sep 26, 2017 |
KalVista Pharmaceuticals
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $12.40
Upside: +61.36%
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $109.55
Upside: +4.97%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $6.49
Upside: +85.04%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $13.00
Upside: +115.38%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $16.94
Upside: +136.13%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.43
Upside: +3,189.47%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.08
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.29
Upside: +90.78%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $1.53
Upside: +422.88%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.40
Upside: -28.57%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $4.27
Upside: +40.52%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $45.38
Upside: +5.77%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $20.15
Upside: -10.67%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $41.64
Upside: -18.35%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $57.33
Upside: +126.76%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $18.23
Upside: +777.67%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $191.49
Upside: -14.88%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.76
Upside: +468.18%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.07
Upside: +2,984.11%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $11.37
Upside: +5.54%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $27.54
Upside: +292.16%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $26.85
Upside: +45.25%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $0.81
Upside: +395.66%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $12.68
Upside: +136.59%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $46.29
Upside: +8.01%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $51.06
Upside: -41.25%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $13.28
Upside: +321.69%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $6.77
Upside: +106.95%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.17
Upside: +453.00%